Lukasz A Malek

Summary

Affiliation: Instytut Kardiologii
Country: Poland

Publications

  1. pmc LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
    Michal Saj
    Laboratory of Molecular Biology, Institute of Cardiology, Warsaw, Alpejska 42 04 628, Poland
    BMC Med Genet 14:55. 2013
  2. doi request reprint The size does not matter - the presence of microvascular obstruction but not its extent corresponds to larger infarct size in reperfused STEMI
    Łukasz A Małek
    Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
    Eur J Radiol 81:2839-43. 2012
  3. ncbi request reprint Cardiac magnetic resonance imaging in patients with Fabry's disease
    Lukasz A Małek
    Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
    Kardiol Pol 68:929-34. 2010
  4. ncbi request reprint Left ventricular diastolic function assessed with cardiovascular magnetic resonance imaging and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy
    Lukasz A Małek
    Klinika Choroby Wiencowej, Instytut Kardiologii, ul Alpejska 42, 04 628 Warszawa, Poland
    Kardiol Pol 67:1-6; discussion 7-8. 2009
  5. doi request reprint Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation
    Lukasz A Malek
    1st Department of Coronary Artery Disease and Catheterization Laboratory, Institute of Cardiology, Warsaw, Poland
    Eur J Heart Fail 10:1123-6. 2008
  6. ncbi request reprint Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel
    Lukasz A Malek
    Coronary Disease Department and II Catheterization Laboratory, Institute of Cardiology, Alpejska 42 str, 04 628 Warsaw, Poland
    Circ J 72:1165-9. 2008
  7. doi request reprint Cardioverter-defibrillator lead-related thrombus treated with prolonged anticoagulation in patient with prothrombotic disorder
    Lukasz A Malek
    1st Department of Coronary Artery Disease and 2nd Catheterization Laboratory, Institute of Cardiology, Warsaw, Poland
    Blood Coagul Fibrinolysis 19:319-21. 2008
  8. doi request reprint The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy
    Mariusz Klopotowski
    1st Department of Coronary Artery Disease and 2nd Catheterization Laboratory, Institute of Cardiology, Alpejska 42, 04 628, Warsaw, Poland
    Clin Res Cardiol 99:285-92. 2010
  9. doi request reprint Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy
    Mateusz Spiewak
    First Department of Coronary Artery Disease, Magnetic Resonance Unit, Institute of Cardiology, ul Alpejska 42, 04 628 Warsaw, Poland
    Eur J Radiol 74:e149-53. 2010
  10. ncbi request reprint Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty--influence on myocardial reperfusion, left ventricular performance, and clinical events
    Zenon Huczek
    1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
    Am Heart J 154:62-70. 2007

Collaborators

Detail Information

Publications20

  1. pmc LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
    Michal Saj
    Laboratory of Molecular Biology, Institute of Cardiology, Warsaw, Alpejska 42 04 628, Poland
    BMC Med Genet 14:55. 2013
    ..The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro...
  2. doi request reprint The size does not matter - the presence of microvascular obstruction but not its extent corresponds to larger infarct size in reperfused STEMI
    Łukasz A Małek
    Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
    Eur J Radiol 81:2839-43. 2012
    ..It remains unresolved whether the infarct size corresponds only to the presence of MVO or also to its extent...
  3. ncbi request reprint Cardiac magnetic resonance imaging in patients with Fabry's disease
    Lukasz A Małek
    Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
    Kardiol Pol 68:929-34. 2010
    ....
  4. ncbi request reprint Left ventricular diastolic function assessed with cardiovascular magnetic resonance imaging and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy
    Lukasz A Małek
    Klinika Choroby Wiencowej, Instytut Kardiologii, ul Alpejska 42, 04 628 Warszawa, Poland
    Kardiol Pol 67:1-6; discussion 7-8. 2009
    ..Cardiovascular magnetic resonance (CMR) imaging has become a useful tool in diagnosis, risk stratification and treatment monitoring in patients with HCM...
  5. doi request reprint Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation
    Lukasz A Malek
    1st Department of Coronary Artery Disease and Catheterization Laboratory, Institute of Cardiology, Warsaw, Poland
    Eur J Heart Fail 10:1123-6. 2008
    ..In hypertrophic obstructive cardiomyopathy, percutaneous transluminal septal myocardial ablation (PTSMA) improves functional capacity in the short term. However, long term functional capacity is unknown...
  6. ncbi request reprint Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel
    Lukasz A Malek
    Coronary Disease Department and II Catheterization Laboratory, Institute of Cardiology, Alpejska 42 str, 04 628 Warsaw, Poland
    Circ J 72:1165-9. 2008
    ..Coexisting polymorphisms of the genes affecting clopiogrel resistance may influence platelet activation...
  7. doi request reprint Cardioverter-defibrillator lead-related thrombus treated with prolonged anticoagulation in patient with prothrombotic disorder
    Lukasz A Malek
    1st Department of Coronary Artery Disease and 2nd Catheterization Laboratory, Institute of Cardiology, Warsaw, Poland
    Blood Coagul Fibrinolysis 19:319-21. 2008
    ..It led to a complete resolution of the thrombus in 4 weeks without the need for a high-risk operation in this patient...
  8. doi request reprint The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy
    Mariusz Klopotowski
    1st Department of Coronary Artery Disease and 2nd Catheterization Laboratory, Institute of Cardiology, Alpejska 42, 04 628, Warsaw, Poland
    Clin Res Cardiol 99:285-92. 2010
    ..The procedure relieves left ventricular outflow tract obstruction, but produces a myocardial scar in patients who already have a substrate for life-threatening ventricular arrhythmia...
  9. doi request reprint Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy
    Mateusz Spiewak
    First Department of Coronary Artery Disease, Magnetic Resonance Unit, Institute of Cardiology, ul Alpejska 42, 04 628 Warsaw, Poland
    Eur J Radiol 74:e149-53. 2010
    ..There is no consensus regarding the technique of quantification of late gadolinium enhancement (LGE). The aim of the study was to compare different methods of LGE quantification in patients with hypertrophic cardiomyopathy (HCM)...
  10. ncbi request reprint Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty--influence on myocardial reperfusion, left ventricular performance, and clinical events
    Zenon Huczek
    1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
    Am Heart J 154:62-70. 2007
    ..We sought to determine whether platelet reactivity predicts impaired myocardial reperfusion, left ventricular (LV) dysfunction, and clinical events in an unselected group of patients with STEMI...
  11. ncbi request reprint Repaired tetralogy of Fallot: ratio of right ventricular volume to left ventricular volume as a marker of right ventricular dilatation
    Mateusz Spiewak
    Department of Coronary Artery Disease and Structural Heart Diseases, Cardiac Magnetic Resonance Unit, Institute of Cardiology, ul Alpejska 42, 04 628 Warsaw, Poland
    Radiology 265:78-86. 2012
    ....
  12. doi request reprint Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality
    Adam Witkowski
    Cardiac Catheterization Laboratory, Institute of Cardiology, 04 628 Warsaw, Poland
    Eur Heart J 30:1736-43. 2009
    ..The aim of this analysis was to examine the influence of different in-cath-lab antiplatelet regimens for the primary percutaneous coronary intervention (PCI) on all-cause mortality...
  13. doi request reprint A new model of home-based telemonitored cardiac rehabilitation in patients with heart failure: effectiveness, quality of life, and adherence
    Ewa Piotrowicz
    Department of Cardiac Rehabilitation and Noninvasive Electrocardiology, Institute of Cardiology, Alpejska 42, Warsaw 04 628, Poland
    Eur J Heart Fail 12:164-71. 2010
    ....
  14. doi request reprint Avoiding pacemaker lead entrapment during PFO closure
    Marcin Demkow
    1st Department of Coronary Artery Disease and 2nd Catheterization Laboratory, Institute of Cardiology, Warsaw, Poland
    Catheter Cardiovasc Interv 72:97-9. 2008
    ..Subsequently, an occluder was successfully placed. In conclusion, difficulties in Amplatzer occluder placement in patients with implanted pacemaker may be overcome by a manoeuvre which prevents lead entrapment by the device...
  15. ncbi request reprint Genetic variants in hypertensive patients with coronary artery disease and coexisting atheromatous renal artery stenosis
    Malgorzata Szperl
    Laboratory of Molecular Biology, Institute of Cardiology, Warsaw, Poland
    Med Sci Monit 14:CR611-6. 2008
    ....
  16. ncbi request reprint Sodium level on admission and in-hospital outcomes of STEMI patients treated with primary angioplasty: the ANIN Myocardial Infarction Registry
    Mariusz Klopotowski
    1st Department of Coronary Artery Disease, Institute of Cardiology, Warsaw, Poland
    Med Sci Monit 15:CR477-83. 2009
    ..This study investigated whether sodium level on admission is predictive of in-hospital outcome in patients with ST-elevation myocardial infarction (STEMI) treated with primary angioplasty...
  17. pmc Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT)
    Lukasz A Malek
    Institute of Cardiology, Warsaw, Poland
    Am Heart J 157:724-32. 2009
    ..We analyzed a prespecified hypothesis of the Occluded Artery Trial (OAT) that late percutaneous coronary intervention (PCI) of the infarct-related artery (IRA) would be most beneficial for patients with anterior myocardial infarction (MI)...
  18. ncbi request reprint Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects
    Lukasz A Malek
    1st Department of Cardiology, Medical University of Warsaw, 1a Banacha Str, Warsaw 02 097, Poland
    J Thromb Thrombolysis 24:301-5. 2007
    ..The study was designed to determine whether impaired antiplatelet response to clopidogrel but not to aspirin may be responsible for loss of pleiotropic effects of the drug...
  19. ncbi request reprint Response to letter of Dr van Werkum et al
    Renata Glowczynska
    Int J Cardiol 119:122-3. 2007
  20. ncbi request reprint Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis--a case report and review of the literature
    Renata Glowczynska
    Int J Cardiol 111:326-8. 2006
    ..Although there is no test recommended to assess the response to the antiplatelet therapy, the presented case suggests platelet function analysis should be undertaken in patients with recurrent stent thrombosis...